Response rate to albumin-bound paclitaxel + gemcitabine + cisplatin among patients with advanced pancreatic cancer
Adding a drug that targets a molecular vulnerability in pancreatic cancer could provide substantial benefit to patients, according to a clinical trial study by the HonorHealth Research Institute and the Translational Genomics ...
Oct 3, 2019
0
1